StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Paid Aristotle tests being performed during Q3

<< Previous

Bullboard Posts

Next >>

Comment by Photoman77on Nov 04, 2021 10:28am

79 Views

Post# 34086416

RE:RE:Paid Aristotle tests being performed during Q3

That is correct. Current patients as well as all relatives who are at risk of developing cancer so test can be taken as precautionary measure.

It's interesting that all the accumulation from certain financial institutions started once the Care Oncology deal closed and the new CFO took control.

<< Previous

Bullboard Posts

Next >>

Southern Ontario mineral processing operation receives green fund support